Forward P/S Multiple: Emergent BioSolutions Inc. (EBS)

EBS (Emergent BioSolutions Inc.) - company brandmark

The foundation of the Emergent BioSolutions (EBS) business is a team of leading biologists developing defense systems. On GURU.Markets, the forward price-to-sales ratio visualizes the valuation trend, where 0.50 serves as the final level marker. The automation of production facilities, which eliminates human error, enhances efficiency. Government vaccine contracts and Narcan sales provide stability, balancing the company's current finances.

EBS emergentbiosolutions.com: Forward Price to Sales in the range 07/04/2022 - 11/13/2026

EBS (Emergent Bio): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Emergent BioSolutions Inc.|EBS - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Emergent Bio|EBS - Total Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Emergent BioSolutions|EBS - Accounting Value of Company|Market Capitalization to Book Value Ratio emergentbiosolutions.com|EBS - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital Emergent BioSolutions|EBS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Emergent BioSolutions|EBS - Company Aggregate Debt|Debt to Book Value Emergent Bio|EBS - Amount of Long-Term Liabilities|Company Current Liabilities Emergent BioSolutions|Quick Ratio emergentbiosolutions.com
- business earnings and investment ratios data:
EBS - Company Net Income|Projected Future Earnings Emergent BioSolutions|EBS - Business Payback Period|Future Price to Earnings Emergent Corp|EBS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Emergent Bio|EBS - Operating income before deduction of amortization|Earnings per share for the last twelve months Emergent BioSolutions|EBS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months emergentbiosolutions.com|EBS - Earnings per share growth in current year|Expected earnings per share growth for next year Emergent BioSolutions
- company sales and revenue statistics:
EBS - Revenue and Sales Volume|Company Future Sales Volume Emergent BioSolutions Inc.|EBS - Market Cap to Sales Volume|Forward P/S Multiple Emergent Bio
Fundamental company valuation:Emergent BioSolutions Inc. (EBS)
Product sample of Emergent BioSolutions

For Emergent BioSolutions (EBS), whose positions are bolstered by government contracts, the forward price-to-sales ratio serves as an indicator of market confidence in future revenue streams. This metric compares current market capitalization with expected sales volume, allowing investors to assess the risk of asset undervaluation against the costs of remediating manufacturing violations required by the FDA.

Competing companies

Price-to-Projected Revenue Ratio Gilead Sciences GILD|CDTX - Forward Price-to-Revenue Multiple|Novavax Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio CureVac Pharma|Valneva SE (VALN) - Price-to-Projected Revenue Ratio|vir.bio - Forward Price to Sales|SIGA (SIGA Technologies) - Forward P/S Multiple|AVIR - Projected Price to Revenue|Forward P/S Multiple IVVD|ENTA - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Inovio Pharmaceuticals INO|HLVX: Market Cap to Projected Revenue|KLRS: Forward Price-to-Revenue Multiple|Dyadic International - Price to Expected Revenue Ratio|NNVC (nanoviricides.com) - Forward Price-to-Revenue Multiple|Talphera Corporation - Forward Price to Sales|COCP (Cocrystal Pharma, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TRAW|Forward P/S Multiple DWTX|Market Cap to Expected Sales Ratio Qualigen Therapeutics Inc|Price-to-Projected Revenue Ratio AlloVir ALVR|VBI Vaccines, Inc. (VBIV) - Market Cap to Future Revenue Ratio|VIRI - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Vaxart, Inc. VXRT